|
1
|
Chan YS, Cheng LN, Wu JH, Chan E, Kwan YW,
Lee SM, Leung GP, Yu PH and Chan SW: A review of the
pharmacological effects of Arctium lappa (burdock).
Inflammopharmacology. 19:245–254. 2011. View Article : Google Scholar
|
|
2
|
Hayashi K, Narutaki K, Nagaoka Y, Hayashi
T and Uesato S: Therapeutic effect of arctiin and arctigenin in
immunocompetent and immunocompromised mice infected with influenza
A virus. Biol Pharm Bull. 33:1199–1205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swarup V, Ghosh J, Mishra MK and Basu A:
Novel strategy for treatment of Japanese encephalitis using
arctigenin, a plant lignan. J Antimicrob Chemother. 61:679–688.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim Y, Hollenbaugh JA, Kim DH and Kim B:
Novel PI3K/Akt inhibitors screened by the cytoprotective function
of human immunodeficiency virus type 1 Tat. PLoS One. 6:e217812011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang HS, Lee JY and Kim CJ:
Anti-inflammatory activity of arctigenin from Forsythiae Fructus. J
Ethnopharmacol. 116:305–312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JY and Kim CJ: Arctigenin, a
phenylpropanoid dibenzylbutyrolactone lignan, inhibits type I-IV
allergic inflammation and pro-inflammatory enzymes. Arch Pharm Res.
33:947–957. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zick SM, Sen A, Feng Y, Green J, Olatunde
S and Boon H: Trial of Essiac to ascertain its effect in women with
breast cancer (TEA-BC). J Altern Complement Med. 12:971–980. 2006.
View Article : Google Scholar
|
|
8
|
Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai
EM and Hsu YL: Arctigenin, a dietary phytoestrogen, induces
apoptosis of estrogen receptor-negative breast cancer cells through
the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic Biol
Med. 67:159–170. 2014. View Article : Google Scholar
|
|
9
|
Huang K, Li LA, Meng YG, You YQ, Fu XY and
Song L: Arctigenin promotes apoptosis in ovarian cancer cells via
the iNOS/NO/STAT3/survivin signalling. Basic Clin Pharmacol
Toxicol. 115:507–511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jeong JB, Hong SC, Jeong HJ and Koo JS:
Arctigenin induces cell cycle arrest by blocking the
phosphorylation of Rb via the modulation of cell cycle regulatory
proteins in human gastric cancer cells. Int Immunopharmacol.
11:1573–1577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang X, Zeng L, Huang J, Zhou H and Liu
Y: Arctigenin, a natural lignan compound, induces apoptotic death
of hepatocellular carcinoma cells via suppression of PI3-K/Akt
signaling. J Biochem Mol Toxicol. 29:458–464. 2015. View Article : Google Scholar
|
|
12
|
Kim JY, Hwang JH, Cha MR, Yoon MY, Son ES,
Tomida A, Ko B, Song SW, Shin-ya K, Hwang YI, et al: Arctigenin
blocks the unfolded protein response and shows therapeutic
antitumor activity. J Cell Physiol. 224:33–40. 2010.PubMed/NCBI
|
|
13
|
Susanti S, Iwasaki H, Inafuku M, Taira N
and Oku H: Mechanism of arctigenin-mediated specific cytotoxicity
against human lung adenocarcinoma cell lines. Phytomedicine.
21:39–46. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang HQ, Jin JJ and Wang J: Arctigenin
enhances chemosensitivity to cisplatin in human nonsmall lung
cancer H460 cells through downregulation of survivin expression. J
Biochem Mol Toxicol. 28:39–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Zhao F and Liu K: Induction of
apoptosis of the human leukemia cells by arctigenin and its
mechanism of action. Yao Xue Xue Bao. 43:542–547. 2008.In Chinese.
PubMed/NCBI
|
|
16
|
Yang S, Ma J, Xiao J, Lv X, Li X, Yang H,
Liu Y, Feng S and Zhang Y: Arctigenin anti-tumor activity in
bladder cancer T24 cell line through induction of cell-cycle arrest
and apoptosis. Anat Rec (Hoboken). 295:1260–1266. 2012. View Article : Google Scholar
|
|
17
|
Kang K, Lee HJ, Yoo JH, Jho EH, Kim CY,
Kim M and Nho CW: Cell and nuclear enlargement of SW480 cells
induced by a plant lignan, arctigenin: Evaluation of cellular DNA
content using fluorescence microscopy and flow cytometry. DNA Cell
Biol. 30:623–629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng T, Cao W, Shen W, Zhang L, Gu X, Guo
Y, Tsai HI, Liu X, Li J, Zhang J, et al: Arctigenin inhibits STAT3
and exhibits anticancer potential in human triple-negative breast
cancer therapy. Oncotarget. 8:329–344. 2017.
|
|
19
|
Maxwell T, Chun SY, Lee KS, Kim S and Nam
KS: The anti-metastatic effects of the phytoestrogen arctigenin on
human breast cancer cell lines regardless of the status of ER
expression. Int J Oncol. 50:727–735. 2017. View Article : Google Scholar
|
|
20
|
Wu X, Tong B, Yang Y, Luo J, Yuan X, Wei
Z, Yue M, Xia Y and Dai Y: Arctigenin functions as a selective
agonist of estrogen receptor β to restrict mTORC1 activation and
consequent Th17 differentiation. Oncotarget. 7:83893–83906. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bardin A, Boulle N, Lazennec G, Vignon F
and Pujol P: Loss of ERbeta expression as a common step in
estrogen-dependent tumor progression. Endocr Relat Cancer.
11:537–551. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Skliris GP, Munot K, Bell SM, Carder PJ,
Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF, et
al: Reduced expression of oestrogen receptor beta in invasive
breast cancer and its re-expression using DNA methyl transferase
inhibitors in a cell line model. J Pathol. 201:213–220. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie LH, Ahn EM, Akao T, Abdel-Hafez AA,
Nakamura N and Hattori M: Transformation of arctiin to estrogenic
and antiestrogenic substances by human intestinal bacteria. Chem
Pharm Bull (Tokyo). 51:378–384. 2003. View Article : Google Scholar
|
|
24
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang Y, Yan C and Schor NF: Apoptosis in
the absence of caspase 3. Oncogene. 20:6570–6578. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vandenabeele P, Galluzzi L, Vanden Berghe
T and Kroemer G: Molecular mechanisms of necroptosis: An ordered
cellular explosion. Nat Rev Mol Cell Biol. 11:700–714. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu X, Wu MY, Jiang M, Zhi Q, Bian X, Xu
MD, Gong FR, Hou J, Tao M, Shou LM, et al: TNF-α sensitizes
chemotherapy and radiotherapy against breast cancer cells. Cancer
Cell Int. 17:132017. View Article : Google Scholar
|
|
28
|
Jung CH, Ro SH, Cao J, Otto NM and Kim DH:
mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gu Y, Sun XX, Ye JM, He L, Yan SS, Zhang
HH, Hu LH, Yuan JY and Yu Q: Arctigenin alleviates ER stress via
activating AMPK. Acta Pharmacol Sin. 33:941–952. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu X, Dou Y, Yang Y, Bian D, Luo J, Tong
B, Xia Y and Dai Y: Arctigenin exerts anti-colitis efficacy through
inhibiting the differentiation of Th1 and Th17 cells via an
mTORC1-dependent pathway. Biochem Pharmacol. 96:323–336. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu Z, Yan J, Jiang W, Yao XG, Chen J,
Chen L, Li C, Hu L, Jiang H and Shen X: Arctigenin effectively
ameliorates memory impairment in Alzheimer's disease model mice
targeting both β-amyloid production and clearance. J Neurosci.
33:13138–13149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoshioka A, Miyata H, Doki Y, Yamasaki M,
Sohma I, Gotoh K, Takiguchi S, Fujiwara Y, Uchiyama Y and Monden M:
LC3, an autophagosome marker, is highly expressed in
gastrointestinal cancers. Int J Oncol. 33:461–468. 2008.PubMed/NCBI
|
|
33
|
Chanoux RA, Yin B, Urtishak KA, Asare A,
Bassing CH and Brown EJ: ATR and H2AX cooperate in maintaining
genome stability under replication stress. J Biol Chem.
284:5994–6003. 2009. View Article : Google Scholar :
|
|
34
|
Koehn H, Magan N, Isaacs RJ and Stowell
KM: Differential regulation of DNA repair protein Rad51 in human
tumour cell lines exposed to doxorubicin. Anticancer Drugs.
18:419–425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maier P, Hartmann L, Wenz F and Herskind
C: Cellular pathways in response to ionizing radiation and their
targetability for tumor radiosensitization. Int J Mol Sci. 17:1–32.
2016. View Article : Google Scholar
|
|
36
|
Meijer AJ and Codogno P: Autophagy:
Regulation by energy sensing. Curr Biol. 21:R227–R229. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shagufta and Ahmad I: Tamoxifen a
pioneering drug: An update on the therapeutic potential of
tamoxifen derivatives. Eur J Med Chem. 143:515–531. 2018.
View Article : Google Scholar
|
|
38
|
Lonard DM, Nawaz Z, Smith CL and O'Malley
BW: The 26S proteasome is required for estrogen receptor-alpha and
coactivator turnover and for efficient estrogen receptor-alpha
transactivation. Mol Cell. 5:939–948. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pinzone JJ, Stevenson H, Strobl JS and
Berg PE: Molecular and cellular determinants of estrogen receptor
alpha expression. Mol Cell Biol. 24:4605–4612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cui X, Zhang P, Deng W, Oesterreich S, Lu
Y, Mills GB and Lee AV: Insulin-like growth factor-I inhibits
progesterone receptor expression in breast cancer cells via the
phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin
pathway: Progesterone receptor as a potential indicator of growth
factor activity in breast cancer. Mol Endocrinol. 17:575–588. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rice S and Whitehead SA: Phytoestrogens
and breast cancer–promoters or protectors? Endocr Relat Cancer.
13:995–1015. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Matsumura A, Ghosh A, Pope GS and Darbre
PD: Comparative study of oestrogenic properties of eight
phytoestrogens in MCF7 human breast cancer cells. J Steroid Biochem
Mol Biol. 94:431–443. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee J, Imm JY and Lee SH: β-catenin
mediates anti-adipogenic and anticancer effects of arctigenin in
preadipocytes and breast cancer cells. J Agric Food Chem.
65:2513–2520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lui A, New J, Ogony J, Thomas S and
Lewis-Wambi J: Everolimus downregulates estrogen receptor and
induces autophagy in aromatase inhibitor-resistant breast cancer
cells. BMC Cancer. 16:4872016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nathan MR and Schmid P: A review of
fulvestrant in breast cancer. Oncol Ther. 5:17–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miller TW, Hennessy BT, González-Angulo
AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y
and Arteaga CL: Hyperactivation of phosphatidylinositol-3 kinase
promotes escape from hormone dependence in estrogen
receptor-positive human breast cancer. J Clin Invest.
120:2406–2413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chumsri S, Sabnis G, Tkaczuk K and Brodie
A: mTOR inhibitors: Changing landscape of endocrine-resistant
breast cancer. Future Oncol. 10:443–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ghayad SE, Bieche I, Vendrell JA, Keime C,
Lidereau R, Dumontet C and Cohen PA: mTOR inhibition reverses
acquired endocrine therapy resistance of breast cancer cells at the
cell proliferation and gene-expression levels. Cancer Sci.
99:1992–2003. 2008.PubMed/NCBI
|
